doi:10.3969/j.issn.1673-8640.2015.09.011

Abstract

CLC Number:

R446.11

Figures/Tables 6

References 14

[1]	邱志琦,温少磊,谭智毅.胃蛋白酶原Ⅰ、Ⅱ及其比值在胃癌筛查中的应用[J]. 检验医学与临床,2013,10(14): 1806-1807.
[2]	项文坤,熊锋宝,杨铁一,等.血清唾液酸上皮膜抗原及甘氨酰脯氨酸二肽氨基肽酶单项及联合检测诊断胃癌的临床研究[J]. 中国实用内科杂志,2009,29(11):1012-1014.
[3]	徐光炜. 新编常见恶性肿瘤诊治规范——胃癌分册[M].北京:北京医科大学中国协和医科大学联合出版社,1999:40-47.
[4]	梁军. 血清胃蛋白酶原在胃腺癌诊断中的临床价值[J].全科医学临床与教育,2014,12(3):247-249.
[5]	KAGEYAMA T.Pepsinogens,progastricsins,and prochymosins: structure,function,evolution,and development[J]. Cell Mol Life Sci,2002,59(2):288-306.
[6]	张金锋. 血清胃蛋白酶原、CEA、CA19-9及CA72-4检测对胃癌的诊断价值探讨[J]. 检验医学,2014,29(8): 831-834.
[7]	卢灿荣,张士武,张勇,等. 癌胚抗原、糖链抗原72-4和胃蛋白酶原联合检测评价胃癌的诊断价值[J]. 检验医学,2012,27(6): 442-444.
[8]	费凤英,王金金,祝新华. 血清胃蛋白酶原检测在胃癌诊治中的应用进展[J].医学信息,2011,24(3):1461-1463.
[9]	赵兰静,刘春兴,安仙园. 血清胃蛋白酶原和抗Hp IgG抗体对消化性溃疡的临床意义[J]. 检验医学,2014,29(11): 1124-1127.
[10]	KONTUREK PC,KONTUREK SJ,BRZOZOWSKI T.Helicobacter pylori infection in gastric cancerogenesis[J]. J Physiol Pharmacol,2009,60(3):3-21.
[11]	LORENTE S,DOIZ O,TRINIDAD SERRANO M,et al.Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells[J]. Gut,2002,50(1): 13-18.
[12]	SUN LP,GONG YH,WANG L, et al . Serum pepsinogen levels and their influencing factors: a population-based study in 6 990 Chinese from North China[J]. World J Gastroenterol,2007,13( 48): 6562-6567.
[13]	OISHI Y,KIYOHARA Y,KUBO M,et al.The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study[J]. Am J Epidemiol,2006,163(7):629-637.
[14]	赵瑶,刘银梅,胡文斌,等. 胃蛋白酶原在癌前病变、胃癌诊断中的应用进展[J]. 实用癌症杂志,2011,26(2):205-207.

组别	例数	PGⅠ(ng/mL)	PGⅡ(ng/mL)	PGR	GPDA(U/L)
胃癌组	50	67.96±17.24^*#Δ▲▲	25.27±4.63^*#Δ※	2.75±0.86^*#Δ▲▲	54.78±13.16^*#Δ▲▲
慢性萎缩性胃炎组	50	89.22±24.39^*	23.37±4.84^*	4.04±1.41*	65.72±15.26^*
浅表性胃炎组	50	126.50±31.25^Δ▲▲	20.36±7.06^Δ▲	6.43±0.88^Δ▲▲	75.00±11.97^▲▲
胃溃疡组	50	178.22±48.76^*▲▲	31.77±8.78^*▲▲	5.73±1.28^*▲▲	75.34±12.99^▲▲
正常对照组	50	132.44±21.96	20.77±4.42	6.53±1.25	74.88±13.53

组别	例数	PGⅠ(ng/mL)	PGⅡ(ng/mL)	PGR	GPDA(U/L)
胃癌组	50	67.96±17.24^*#Δ▲▲	25.27±4.63^*#Δ※	2.75±0.86^*#Δ▲▲	54.78±13.16^*#Δ▲▲
慢性萎缩性胃炎组	50	89.22±24.39^*	23.37±4.84^*	4.04±1.41*	65.72±15.26^*
浅表性胃炎组	50	126.50±31.25^Δ▲▲	20.36±7.06^Δ▲	6.43±0.88^Δ▲▲	75.00±11.97^▲▲
胃溃疡组	50	178.22±48.76^*▲▲	31.77±8.78^*▲▲	5.73±1.28^*▲▲	75.34±12.99^▲▲
正常对照组	50	132.44±21.96	20.77±4.42	6.53±1.25	74.88±13.53

组别	例数	Hp阳性
组别	例数	阳性例数(%)	PGⅠ(ng/mL)	PGⅡ(ng/mL)		PGR	GPDA(U/L)
胃癌组	50	38(76)	66.37±18.86	24.52±4.71		2.78±0.97	54.16±12.01
浅表性胃炎组	50	34(68)	131.41±28.69	20.99±6.27		6.45±0.97	75.00±11.41
胃溃疡组	50	40(80)	180.28±45.94	31.60±8.76		5.86±1.33	75.80±13.36
慢性萎缩性胃炎组	50	36(72)	86.14±21.66	22.92±4.16		3.99±1.38	65.69±13.48
正常对照组	50	29(58)	132.83±18.59	20.23±3.99		6.75±1.42	75.28±13.40
组别	例数	Hp阴性
组别	例数	阴性例数(%)	PGⅠ(ng/mL)	PGⅡ(ng/mL)	PGR			GPDA(U/L)
胃癌组	50	12(24)	73.00±9.51	27.67±3.57	2.66±0.34		56.75±16.65
浅表性胃炎组	50	16(32)	116.06±34.74	19.03±8.58	6.38±0.70		75.00±13.49
胃溃疡组	50	10(20)	170.01±60.90	32.48±9.31	5.21±0.93		73.50±11.85
慢性萎缩性胃炎组	50	14(28)	97.14±29.75	24.53±6.30	4.16±1.51		67.14±19.26
正常对照组	50	21(42)	131.90±26.41	21.52±4.96	6.22±0.91		74.33±14.03

组别	例数	Hp阳性
组别	例数	阳性例数(%)	PGⅠ(ng/mL)	PGⅡ(ng/mL)		PGR	GPDA(U/L)
胃癌组	50	38(76)	66.37±18.86	24.52±4.71		2.78±0.97	54.16±12.01
浅表性胃炎组	50	34(68)	131.41±28.69	20.99±6.27		6.45±0.97	75.00±11.41
胃溃疡组	50	40(80)	180.28±45.94	31.60±8.76		5.86±1.33	75.80±13.36
慢性萎缩性胃炎组	50	36(72)	86.14±21.66	22.92±4.16		3.99±1.38	65.69±13.48
正常对照组	50	29(58)	132.83±18.59	20.23±3.99		6.75±1.42	75.28±13.40
组别	例数	Hp阴性
组别	例数	阴性例数(%)	PGⅠ(ng/mL)	PGⅡ(ng/mL)	PGR			GPDA(U/L)
胃癌组	50	12(24)	73.00±9.51	27.67±3.57	2.66±0.34		56.75±16.65
浅表性胃炎组	50	16(32)	116.06±34.74	19.03±8.58	6.38±0.70		75.00±13.49
胃溃疡组	50	10(20)	170.01±60.90	32.48±9.31	5.21±0.93		73.50±11.85
慢性萎缩性胃炎组	50	14(28)	97.14±29.75	24.53±6.30	4.16±1.51		67.14±19.26
正常对照组	50	21(42)	131.90±26.41	21.52±4.96	6.22±0.91		74.33±14.03

项目	最佳临界值	灵敏度(%)	特异度(%)	阳性预测值(%)	阴性预测值(%)
PGⅠ	80.50 ng/mL	66.00	76.00	70.37	73.91
PGⅡ	25.70 ng/mL	32.00	50.00	60.98	57.63
PGR	3.28	72.00	90.00	76.27	87.80
GPDA	57.50 U/L	72.00	62.00	68.89	65.45

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 14

Related Articles 15

Recommended Articles

Metrics

项目	AUC	标准误	P值	95%可信区间
PGⅠ	0.763	0.048	0.000	0.669~0.857
PGⅡ	0.397	0.056	0.075	0.286~0.507
PGR	0.801	0.046	0.000	0.710~0.892
GPDA	0. 715	0.052	0.000	0.613~0.817

项目	灵敏度	特异度	阳性预测值	阴性预测值
PGⅠ并联PGR	86.00	76.00	78.18	73.33
PGⅠ并联GPDA	76.00	70.00	76.74	61.40
PGR并联GPDA	84.00	78.00	77.78	82.61
PGⅠ并联PGR并联GPDA	92.00	72.00	85.19	78.26

[1]	DENG Chenxia, MEI Yanping, ZHANG Xia, HUANG Baoshan, TIAN Dan, CAO Mengting, HU Yongqi, LIN Yongping, TIAN Lijun. Depolymerization effect of optical platelet count on reversible platelet aggregation after blood collection [J]. Laboratory Medicine, 2023, 38(11): 1087-1090.
[2]	LU Tingyan, GU Danfeng, WANG Yahong, GE Yafang, YANG Haiou. Evaluation of vaginal secretion routine determination modes and review criteria analysis [J]. Laboratory Medicine, 2023, 38(11): 1091-1097.
[3]	. [J]. Laboratory Medicine, 2023, 38(11): 1098-1100.
[4]	. [J]. Laboratory Medicine, 2023, 38(10): 983-986.
[5]	. [J]. Laboratory Medicine, 2023, 38(9): 901-904.
[6]	. [J]. Laboratory Medicine, 2023, 38(9): 905-908.
[7]	CHENG Xu, YANG Cunqing, PANG Bo, GU Chun, HOU Xueyun, FEI Jiaxin, WU Min, LI Jun, LIU Guijian. Number and activity of peripheral blood eosinophils in obese people [J]. Laboratory Medicine, 2023, 38(9): 855-859.
[8]	LEI Jing, MAN Qiuhong, ZHAO Renjia, ZHANG Tiejun, JIANG Yanfeng, XU Kelin, SUO Chen, CHEN Xingdong. Elevated red blood cell distribution width increasing the risk of heart failure：a cohort study based on the UK Biobank [J]. Laboratory Medicine, 2023, 38(9): 860-864.
[9]	DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674.
[10]	XIA Yanyan, XIA Yongquan, SONG Guanghao, XIA Mao. Role of coagulation-related monitoring indicators in the course of rivaroxaban anticoagulation for acute venous thromboembolism in elderly patients [J]. Laboratory Medicine, 2023, 38(5): 475-478.
[11]	CHEN Yi, WANG Jia, XU Zhiwei, ZHAI Yaping, XUAN Weixia. Effects of different anticoagulants on phagocytosis，activation and apoptosis of in vitro neutrophil function [J]. Laboratory Medicine, 2023, 38(5): 479-483.
[12]	YANG Liyuan, DAI Wanqin, WANG Xiaotong, LOU Xiaoli, WANG Yue, HOU Yanqiang. Effect of peripheral blood neutrophils on interferon-gamma release assay of Mycobacterium tuberculosis [J]. Laboratory Medicine, 2023, 38(5): 484-488.
[13]	. [J]. Laboratory Medicine, 2023, 38(5): 502-504.
[14]	. [J]. Laboratory Medicine, 2023, 38(1): 69-72.
[15]	XIE Yuan, YI Wanwan, SHI Qiuyuan, LÜ Zhongwei, LIU Jin. Clinical value of thromboelastography and conventional coagulation tests in evaluating coagulation status of colon cancer and colon polyps [J]. Laboratory Medicine, 2022, 37(11): 1007-1011.